REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024
/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations on its program for the treatment of mucopolysaccharidosis type II (MPS II), also...
Source: prnewswire.com